Aurinia Pharmaceuticals Inc
SWB:IKAP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Aurinia Pharmaceuticals Inc
SWB:IKAP
|
CA |
|
N
|
Novo Nordisk A/S
XBER:NOV
|
DK |
|
Elicio Therapeutics Inc
NASDAQ:ELTX
|
US |
Wall St Price Targets
IKAP Price Targets Summary
Aurinia Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for IKAP is 14.581 EUR with a low forecast of 12.74 EUR and a high forecast of 18.542 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is IKAP's stock price target?
Price Target
14.581
EUR
According to Wall Street analysts, the average 1-year price target for IKAP is 14.581 EUR with a low forecast of 12.74 EUR and a high forecast of 18.542 EUR.
What is the Revenue forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
14%
Over the last 14 years, the compound annual growth rate for Revenue has been 50%. The projected CAGR for the next 8 years is 14%.
What is the Operating Income forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
22%
The compound annual growth rate for Operating Income over the next 8 years is 22%.
What is the Net Income forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
1%
The compound annual growth rate for Net Income over the next 8 years is 1%.
